Lung Cancer clinical trials in West Virginia

9 actively recruiting lung cancer trials at 3 sites across West Virginia.

Data from ClinicalTrials.gov · last refreshed 2026-09-07

Phase 3 Recruiting NIH

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06096844

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06498635

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.

NCT ID: NCT04613596

Sites in West Virginia:

Local Institution - Unk064 — Huntington, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06077760

Sites in West Virginia:

Edwards Comprehensive Cancer Center ( Site 4015) — Huntington, West Virginia

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).

Sponsor: Amgen

NCT ID: NCT07005128

Sites in West Virginia:

West Virginia University Health Sciences Center — Morgantown, West Virginia

View on ClinicalTrials.gov →

Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences

NCT ID: NCT06418204

Sites in West Virginia:

Edwards Comprehensive Cancer Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Phase 4 Recruiting Industry

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…

Sponsor: AstraZeneca

NCT ID: NCT07357597

Sites in West Virginia:

Research Site — Charleston, West Virginia
Research Site — Morgantown, West Virginia

View on ClinicalTrials.gov →

Recruiting Academic/Other

RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most …

Sponsor: The Radiosurgery Society

NCT ID: NCT01885299

Sites in West Virginia:

St. Mary's Medical Center — Huntington, West Virginia

View on ClinicalTrials.gov →

Recruiting Academic/Other

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung…

Sponsor: Scientific Institute San Raffaele

NCT ID: NCT06626243

Sites in West Virginia:

West Virginia University — Morgantown, West Virginia

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07